Susceptibility‐Guided Versus Empirical First‐Line Therapy of Helicobacter pylori Infection in Adults: A Systematic Review and Meta‐Analysis
Helicobacter · 2026-03 · 31 (2)
DOI: 10.1111/hel.70125 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Helicobacter, online erschienen am 14.04.2026. Verfasst von Manuel Coelho Rocha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Unilabs, Lisbon, Portugal. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Antimicrobial resistance undermines empirical first‐line regimens for Helicobacter pylori . We compared susceptibility‐guided therapy (SGT) versus empirical therapy in adults receiving first‐line treatment, focusing on intention‐to‐treat (ITT) eradication. Materials and Methods We searched MEDLINE (PubMed), Web of Science, and Scopus from inception to 30 September 2025 for randomized controlled trials (RCTs) and non‐randomized comparative studies (NRS) in adults with confirmed H. pylori . Interventions included phenotypic (culture/E‐test) or genotypic (PCR) SGT applied to biopsy, stool, or gastric juice specimens; comparators were empirical regimens including bismuth quadruple therapy (BQT) and non‐BQT options. The primary outcome was ITT eradication. We pooled risk ratios (RR) with DerSimonian–Laird random‐effects, reported I 2 /τ 2 , and derived 95% prediction intervals (PI). Subgroups were prespecified by comparator family (BQT vs. other) and specimen/method. Multi‐arm studies combined empirical arms within family or split across distinct families.
Results
Forty‐two studies met inclusion criteria; all contributed ITT data. RCTs (k = 33) favored SGT over empirical therapy (pooled RR 1.09, 95% CI 1.05–1.13; I 2 73%; 95% PI 0.92–1.30). NRS (k = 12) were directionally consistent (pooled RR 1.15, 95% CI 1.10–1.22; I 2 75%; 95% PI 0.99–1.35). In RCTs, effects were neutral‐to‐modest vs. BQT (RR 1.03, 95% CI 0.97–1.10) and clearer vs. other empirical regimens (RR 1.12, 95% CI 1.06–1.18).
Conclusions
In adult first‐line therapy, SGT achieves at least non‐inferior—and often superior—eradication versus empirical regimens; the incremental benefit is attenuated where BQT is standard. These findings support selective, and increasingly justified, integration of susceptibility testing in settings with clinically relevant resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unilabs, Lisbon, Portugal.
- NOVA Medical School, Universidade NOVA de Lisboa, Lisboa, Portugal.
- Department of Gastroenterology, Unidade Local de Saúde de São José, Lisboa, Portugal.
- Department of Surgery and Physiology, Faculty of Medicine, University of Porto (FMUP), Porto, Portugal.
- RISE@CI-IPO (Health Research Network), IPO-Porto, Porto, Portugal.
ORCID-Profile: Manuel Coelho Rocha
Zitieren
APA
Rocha, M. C., Gaspar, T., Bernardes, C., & Nunes, P. P. (2026). Susceptibility‐Guided Versus Empirical First‐Line Therapy of Helicobacter pylori Infection in Adults: A Systematic Review and Meta‐Analysis. Helicobacter, 31(2). https://doi.org/10.1111/hel.70125
Vancouver
Rocha MC, Gaspar T, Bernardes C, Nunes PP. Susceptibility‐Guided Versus Empirical First‐Line Therapy of Helicobacter pylori Infection in Adults: A Systematic Review and Meta‐Analysis. Helicobacter. 2026;31(2). doi:10.1111/hel.70125
BibTeX
@article{Rocha2026,
author = {Rocha, Manuel Coelho and Gaspar, Tiago and Bernardes, Carlos and Nunes, Pedro Pimentel},
title = {Susceptibility‐Guided Versus Empirical First‐Line Therapy of Helicobacter pylori Infection in Adults: A Systematic Review and Meta‐Analysis},
journal = {Helicobacter},
year = {2026},
volume = {31},
number = {2},
doi = {10.1111/hel.70125}
}
EUVIMED